Press release no 5 -2015
Targovax has appointed Peter Skorpil as Head of Business Development, effective from April 8th, 2015. Peter Skorpil, PhD, MBA, VP Business Development, has extensive experience in licensing, commercial assessments, business intelligence and partnering.
Press release no 4 - 2015
TG01, a novel peptide vaccine against cancer specific RAS mutations, is tested in combination with gemcitabine as adjuvant treatment in resected pancreatic cancer.
Mr. Øystein Soug, has been the CFO of the late-stage oncology biotech company Algeta ASA since 2008, building up the functions of Finance, IR, Compliance, IT and HR. During Mr. Soug’s period at Algeta, the company raised USD 200m capital, launched Xofigo, established production and sales in the USA, partnered with and was acquired by Bayer AG.Read more
Targovax: Interim Report Q4 and YTD 2014 (pdf)Read more
The Board of Directors convenes an extraordinary general meeting of Targovax AS on Wednesday, February 11th, 2015, at 12:00 at the company's premises in Vollsveien 6, NO-1366 Lysaker.Read more
Press release no 2 -2015
Targovax has appointed two highly experienced executives to key leadership roles in the company, effective from January 5th, 2015